HORSHAM, Pa., July 23, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the closing of its previously announced registered direct offering priced at-the-market under Nasdaq rules for the issuance and sale of 665,136 shares of its common stock at an average purchase price of $3.16 per share for total gros ...

HORSHAM, Penn., July 22, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the approval of its XTRAC Momentum™ 1.0 device by the Ministry of Health, Labor and Welfare of Japan. The Company initially launched the XTRAC Momentum™ in the U.S. in early 2022. The immediate commercial rollout of the device in J ...

Study published in Journal of Cosmetic and Laser Therapy highlights the TheraClear®X photopneumatic device as an effective treatment option, either as monotherapy or in combination with topical or oral treatments, for patients with mild-moderate acne HORSHAM, Pa., July 17, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic cond ...

HORSHAM, Penn., June 12, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces the availability of two virtual webinars that discuss the benefits of using its XTRAC® excimer device for the treatment of psoriasis, vitiligo, and eczema and its TheraClear®X photopneumatic device for the treatment of mild to mode ...

HORSHAM, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. ("STRATA" or the "Company") (NASDAQ:SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults," in the June 2024 issue of ...

HORSHAM, Pa., June 07, 2024 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, today announces the publication of a clinical study titled, " A 7-Week Open-Label Trial Evaluating the Safety and Efficacy of TheraClear®X for Mitigating Mild-to-Moderate Acne in Healthy Adolescents and Young Adults," in the June 2024 issue o ...

财务数据和关键指标变化 - 公司2024年第一季度总收入为6.8百万美元,较2023年同期的7.6百万美元下降[27] - 2024年第一季度全球经常性收入为4.7百万美元,较2023年同期的5.2百万美元下降[28] - 2024年第一季度XTRAC国内经常性总收费为4.6百万美元,较2023年同期的4.7百万美元下降3%[28] - 2024年第一季度设备收入为2.1百万美元,较2023年同期的2.4百万美元下降[28] - 2024年第一季度毛利润为3.1百万美元,较2023年同期的4.4百万美元下降,毛利率从58%下降至45.6%,主要是由于延迟确认2023年第四季度的收入、折旧成本上升、材料和生产成本上升以及存货资产报废所致[29] - 2024年第一季度总运营费用为6百万美元,较2023年同期的7百万美元下降,主要是由于公司在2023年底实施的精简成本结构所致[30] 各条业务线数据和关键指标变化 - XTRAC业务: - 2024年第一季度国内经常性总收费下降3%,这是过去7个季度以来最小的同比下降[16][17] - 公司在2024年第一季度从业绩较差的诊所中移除了32台XTRAC设备,并将16台设备部署到新账户,其中6台部署到之前拥有Excimer激光业务的诊所[18] - 公司预计将继续优化XTRAC设备的部署,将设备从业绩较差的诊所转移到更有潜力的诊所[13][14][15] - TheraClearX业务: - 2024年第一季度TheraClearX设备安装量从2023年末的92台增加到104台[19] - 104台设备中有47家诊所开始使用Acme手术CPT代码进行报销,每周报销65张单据,而去年同期没有任何报销[20] - 公司计划在今年年底或明年第一季度将现有的约200台TheraClearX设备全部部署到市场[44][45] 各个市场数据和关键指标变化 - 国际市场: - 国际收入占公司总收入的30%-35%,其中韩国、中国和日本三个市场占国际收入的50%以上[22] - 公司已经与韩国、中国和日本的独家经销商续签了分销协议[22] - 国内市场: - 公司在2024年第一季度启动了有限区域的DTC营销,并计划在今年内将其扩展到全国所有地区[40][41][42] - 2024年第一季度,公司在6个目标区域通过DTC营销获得了500多个患者预约,每个预约成本不到300美元,每个线索成本不到40美元[11][12] - 公司计划在2024年内将XTRAC设备部署覆盖扩展到全国所有地区[40][41][42] 公司战略和发展方向及行业竞争 - 公司正在实施一项多方位的业务转型战略,主要包括: - 调整XTRAC设备部署,将设备从业绩较差的诊所转移到更有潜力的诊所[13][14][15] - 大幅增加DTC营销投入,以提高XTRAC设备的使用率和每台设备的经常性收入[9][10][11][12] - 严格控制成本,在2024年第一季度将现金消耗和运营费用分别减少41%和14%[24][30] - 公司相信这些策略将有助于实现业务的转型和盈利能力的提升[33][34][35] - 公司拥有XTRAC和TheraClearX两款产品,可以为皮肤科诊所和医疗系统提供可报销的治疗解决方案,从而为公司带来收益[33] 管理层对经营环境和未来前景的评论 - 管理层表示,公司的转型策略正在逐步见效,2024年第一季度国内经常性总收费下降幅度收窄,这为未来几个季度实现收入增长提供了一些乐观预期[16][17] - 管理层认为,通过优化XTRAC设备部署和大幅增加DTC营销投入,公司有望将每台XTRAC设备的年均经常性收入从2023年的21,000美元提高到2019年的30,000美元水平[15] - 管理层表示,公司正在积极控制成本,2024年第一季度已经取得了明显成效,未来将继续保持这种精简的成本结构[24][30] - 管理层对公司的多项战略举措表示信心,认为这些措施将有助于公司实现盈利和正现金流[33][34][35] 问答环节重要的提问和回答 问题1 **Jeffrey Cohen 提问** - 询问公司DTC营销的具体区域覆盖情况,以及到年底的覆盖计划[39][40] **Dolev Rafaeli 回答** - 公司已在4个目标区域启动DTC营销,计划到今年中旬或第三季度中期实现全国范围覆盖[40][41][42] - 公司需要密切关注DTC营销的成本效率,包括每个线索和预约的成本,以及这些预约转化为实际患者治疗的情况[40] 问题2 **Jeffrey Cohen 提问** - 询问公司对XTRAC和TheraClearX设备部署的预期情况[43] **Dolev Rafaeli 回答** - 对于TheraClearX,公司计划在今年年底或明年第一季度将现有约200台设备全部部署到市场[44][45] - 对于XTRAC,公司将继续优化设备部署,从业绩较差的诊所转移到更有潜力的诊所,在充分利用现有923台设备之前不会再增加新设备[46][47][48][49] 问题3 **Jeffrey Cohen 提问** - 询问XTRAC业务的使用情况趋势,以及新增设备部署的情况[49] **Dolev Rafaeli 回答** - 公司将重点提高XTRAC设备的使用率,2023年平均每台设备每季度收入为5,000美元,而2019年为7,

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number: 0-51481 STRATA SKIN SCIENCES, INC. (Exact name of registrant as specified in its charter) Delaware 13-3986004 (State or Other Jurisdiction of incorporation or Organization) (I ...

Exhibit 99.1 STRATA Skin Sciences Reports First Quarter 2024 Financial Results and Provides a Corporate Update HORSHAM, Penn., May 15, 2024 – STRATA Skin Sciences, Inc. (“STRATA” or the “Company”) (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing, and marketing innovative products for the treatment of dermatologic conditions, announces its financial results for the quarter ended March 31, 2024 and provides a corporate update. First Quarter 2024 Highlights • Revenue in the ...

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Q4 2023 Earnings Conference Call March 27, 2024 4:30 PM ET Company Participants Rich Cockrell - Investor Relations Dolev Rafaeli - President & Chief Executive Officer Christopher Lesovitz - Chief Financial Officer Conference Call Participants Jeffrey Cohen - Ladenburg Thalmann Operator Greetings, and welcome to the STRATA Skin Sciences' Fourth Quarter 2023 Earnings Conference Call and Webcast. At this time, all participants are in a listen-only mode. A brief question ...